Baseline Demographics and Disease Characteristics from the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis

被引：0
|
作者：
Steinman, Lawrence [1 ]
Fox, Edward [2 ]
Hartung, Hans-Peter [3 ]
Cree, Bruce [4 ]
Alvarez, Enrique [5 ]
Qian, Peiqing [6 ]
Wray, Sibyl [7 ]
Robertson, Derrick [8 ]
Huang, Deren [9 ]
Selmaj, Krzystof [10 ]
Wynn, Daniel [11 ]
Weiss, Michael [12 ]
Bosco, Jenna [12 ]
Power, Sean [12 ]
Mok, Koby [12 ]
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Cent Texas Neurol Consultants, Round Rock, TX USA
[3] Heinrich Heine Univ, Dusseldorf, Germany
[4] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA
[5] Univ Colorado, Boulder, CO 80309 USA
[6] Swedish Med Ctr, Englewood, CO 80110 USA
[7] Hope Neurol, Knoxville, TN USA
[8] Univ S Florida, Morsani Coll Med, Tampa, FL 33620 USA
[9] Mt Carmel Neurol, Westerville, OH USA
[10] Med Acad Lodz, Lodz, Poland
[11] Consultants Neurol Ltd, Northbrook, IL USA
[12] TG Therapeut, New York, NY USA
来源：
NEUROLOGY | 2020年 / 94卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
4845
引用
收藏
页数：4
相关论文
共 50 条
  • [41] A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
    Sawas, Ahmed
    Farber, Charles M.
    Schreeder, Marshall T.
    Khalil, Mazen Y.
    Mahadevan, Daruka
    Deng, Changchun
    Amengual, Jennifer E.
    Nikolinakos, Petros G.
    Kolesar, Jill M.
    Kuhn, John G.
    Sportelli, Peter
    Miskin, Hari P.
    O'Connor, Owen A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (02) : 243 - 253
  • [42] A phase I dose-escalation trial of ublituximab (TG-1101), a novel anti-CD20 monoclonal antibody (mAb), for rituximab relapsed/refractory B-cell lymphoma patients
    Deng, Changchun
    Amengual, Jennifer Effie
    Schreeder, Marshall T.
    Clark-Garvey, Sean
    Patterson, Molly
    Miskin, Hari
    Sportelli, Peter
    O'Connor, Owen A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
    Salles, Gilles
    Morschhauser, Franck
    Lamy, Thierry
    Milpied, Noel
    Thieblemont, Catherine
    Tilly, Herve
    Bieska, Gabi
    Asikanius, Elina
    Carlile, David
    Birkett, Joe
    Pisa, Pavel
    Cartron, Guillaume
    BLOOD, 2012, 119 (22) : 5126 - 5132
  • [44] Efficacy and Safety in Patients With Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab From Intravenous Anti-CD20 Therapies: Results From the OLIKOS Study
    Hua, Le
    Brown, Brandon
    Camacho, Elizabeth
    Greenberg, Benjamin M.
    Henry, Roland
    Houtsma, Erik
    Alvarez, Enrique
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1167 - 1168
  • [45] Oral Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis: Baseline Patient Demographics and Disease Characteristics from a 2-Year Phase III Trial (FREEDOMS II)
    Calabresi, Peter A.
    Goodin, Douglas
    Jeffery, Douglas
    Lublin, Fred D.
    Rammohan, Kottil
    Reder, Anthony T.
    Vollmer, Timothy
    Stites, Tracy
    Li, Bingbing
    Gottschalk, Rebecca
    Malhotra, Manoj
    NEUROLOGY, 2010, 74 (09) : A416 - A417
  • [46] Retrospective data analysis of a German cohort of patients with active relapsing multiple sclerosis switching from anti-CD20 therapies to cladribine tablets and vice versa
    Konen, Franz Felix
    Pfeuffer, Steffen
    Jendretzky, Konstantin Fritz
    Gehring, Klaus
    Elias-Hamp, Birte
    Suehs, Kurt-Wolfram
    Pawlitzki, Marc
    Meuth, Sven
    Kleinschnitz, Christoph
    Pul, Refik
    Skripuletz, Thomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 328 - 330
  • [47] Oral fingolimod (FTY720) versus interferon beta-1a in relapsing-remitting multiple sclerosis: baseline patient demographics and disease characteristics from a Phase III trial (TRANSFORMS)
    Cohen, Jeffrey
    Pelletier, Jean
    Kappos, Ludwig
    Montalban, Xavier
    Hartung, Hans-Peter
    Comi, Giancarlo
    Khatri, Bhupendra
    Barkhof, Frederik
    Stites, Tracy
    Ohiniann, Harald
    Dong, Victor
    MULTIPLE SCLEROSIS, 2008, 14 : S37 - S37
  • [48] USE OF THE TARGET-MEDIATED DRUG DISPOSITION (TMDD) MODEL TO SUPPORT DOSE SELECTION OF AN OPTIMAL DOSING REGIMEN IN PHASE III TRIALS FOR GA101. THE FIRST TYPE II GLYCOENGINEERED, HUMANIZED MONOCLONAL ANTI-CD20 ANTIBODY.
    Hourcade-Potelleret, F.
    Gibiansky, L.
    le Gallo, C.
    Frey, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S95 - S95
  • [49] Oral fingolimod (FTY720) in relapsing-remitting multiple sclerosis: baseline patient demographics and disease characteristics front a 2-year phase III trial (FREEDOMS)
    Kappos, Ludwig
    Polman, Chris H.
    Radue, Ernst-Wilhelm
    O'Connor, Paul
    Calabresi, Peter A.
    Hohlfeld, Reinhard
    Agoropolou, Catherine
    Pohlmann, Harald
    de Vera, Ana
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 : S50 - S51
  • [50] Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
    Bar-Or, Amit
    Thanei, Gian-Andrea
    Harp, Christopher
    Bernasconi, Corrado
    Bonati, Ulrike
    Cross, Anne H.
    Fischer, Saloumeh
    Gaetano, Laura
    Hauser, Stephen L.
    Hendricks, Robert
    Kappos, Ludwig
    Kuhle, Jens
    Leppert, David
    Model, Fabian
    Sauter, Annette
    Koendgen, Harold
    Jia, Xiaoming
    Herman, Ann E.
    EBIOMEDICINE, 2023, 93
12345